MedTrace Logo

Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)

NCT01155570 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 752

Last updated 2013-10-08

Study results available
· View outcomes & findings →

Summary

The survey will be conducted with regard to the following aspects of treatment with Humira (adalimumab) in patients with psoriasis vulgaris and psoriatic arthritis receiving this drug:

* unknown adverse drug reactions, especially clinically significant adverse reactions
* incidence and conditions of occurrence of adverse reactions in the clinical setting
* factors that may affect the safety and effectiveness of Humira.

Conditions

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Yuji Yamaguchi, MD · AbbVie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01155570 on ClinicalTrials.gov